Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer (NSCLC) is a type of lung cancer that includes several subtypes, primarily affecting the lungs and leading to symptoms such as persistent cough, chest pain, and difficulty breathing.
Lung Cancer Treatment: Telisotuzumab Adizutecan with Osimertinib
We are studying a new combination treatment for adults with advanced EGFR-mutated non-small cell lung cancer. The goal is to see if this approach is safer and more effective than current standard treatments.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you between 18 and 75 years old?
- Do you have any major health problems that could be life-threatening?
- Have you had any cancer in the last 2 years, except for successfully treated skin cancer?
- Do you have any breathing problems like interstitial lung disease or pneumonia that needed treatment?
- Have you had any major surgery or treatment for cancer in the last 3 months?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Telisotuzumab
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Jessa Ziekenhuis
Oncology
Hasselt, Belgium
UZ Leuven
Pulmonology
Heverlee, Belgium
Algemeen Ziekenhuis Delta
Oncology
Rumbeke, Belgium
Sponsor: AbbVie Deutschland GmbH & Co. KG
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.